GlobeNewsWire
20 Aug 2026, 12:52 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Interim Phase 2 data for ART27.13 showed that patients on the highest dose (1300 µg) achieved an average 6% weight gain over 12 weeks, while placebo patients continued to lose weight. — Positive clinical efficacy in an area with no FDA-approved treatment significantly increases the probability of regulatory success and commercial value.
+0.60The Japanese Patent Office has issued a notice of allowance for the commercial formulation of ART27.13, extending protection in the US, Europe, and Japan through 2041. — Securing IP in the three largest pharmaceutical markets reduces long-term legal risk and enhances the asset's attractiveness for potential partnerships or acquisition.
+0.40Initial results from the DREAM Phase 2 study evaluating ART27.13 for glaucoma are anticipated in the fourth quarter of this year. — Provides a near-term catalyst that could either validate the drug's versatility across indications or create a negative sentiment shift.
+0.30Continue reading
6 related stories
Search tags
Which stocks this story touches
The company secured a patent allowance in Japan and reported positive interim Phase 2 clinical data for ART27.13.
Mentioned only as the original developer and licensor of the drug with no current impact on its business.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Globe News Wire
4h ago
GlobeNewsWire
8h ago
